Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Colon CancerColorectal Cancer
Interventions
DRUG

SIR-spheres Agent Administration

SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.

DRUG

Cetuximab

"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."

DRUG

Irinotecan

350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sirtex Medical

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00766220 - Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | Biotech Hunter | Biotech Hunter